Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy

Journal of Inherited Metabolic Disease

Volumn 33, Issue 3, 2010, Pages 281-289

  Marshall, John ^a   McEachern, Kerry Anne ^a   Chuang, Wei Lien ^a   Hutto, Elizabeth ^a   Siegel, Craig S ^a   Shayman, James A ^b   Grabowski, Greg A ^c   Scheule, Ronald K ^a   Copeland, Diane P ^a   Cheng, Seng H ^a  

^a GENZYME CORPORATION   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; GENZ 112638; GLUCOSYLCERAMIDE; IMIGLUCERASE; UNCLASSIFIED DRUG; ELIGLUSTAT; GLUCOSYLCERAMIDASE; PYRROLIDINE DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; LIPID STORAGE; LIVER; LUNG PARENCHYMA; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PHARMACODYNAMICS; SPLEEN; ANIMAL; DISEASE MODEL; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; LYSOSOME; METABOLISM; PROCEDURES; TISSUE DISTRIBUTION;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; IMMUNOHISTOCHEMISTRY; LYSOSOMES; MALE; MICE; PYRROLIDINES; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 77953229219     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9072-z     Document Type: Article

References (41)

1. JM Aerts R Ottenhoff AS Powlson, et al. 2007 Pharmacological inhibition of glucosylceramide synthase enhances insulin sensitivity Diabetes 56 1341 1349 10.2337/db06-1619 1:CAS:528:DC%2BD2sXltlanuro%3D 17287460 (Pubitemid 46715620)
2. Beutler E, Grabowski GA (2001) Gaucher disease. In: Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease (Scriver CR). McGraw-Hill, New York, pp 3635-3668
3. RO Brady JN Kanfer RM Bradley D Shapiro 1966 Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease J. Clin. Invest. 45 1112 1115 10.1172/JCI105417 1:CAS:528:DyaF28XksVWnsLg%3D 5338605
4. J Charrow HC Andersson P Kaplan, et al. 2004 Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations J Pediatr. 144 112 120 10.1016/j.jpeds.2003.10.067 1:CAS:528:DC%2BD2cXosFyg 14722528 (Pubitemid 38091431)
5. TM Cox JM Aerts G Andria, et al. 2003 The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type 1 (non-neuropathic) Gaucher disease: a position statement J. Inherit. Metab. Dis. 26 513 526 10.1023/A:1025902113005 1:CAS:528:DC%2BD3sXns1Cmsrk%3D 14605497 (Pubitemid 37321530)
6. M de Fost CEM Hollack JEM Groener, et al. 2006 Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis Blood 108 830 835 10.1182/blood-2005-12-5072 16527890 (Pubitemid 44154614)
7. T Doering WM Holleran A Potratz G Vielhaber PM Elias K Suzuki K Sandhoff 1999 Sphingolipid activator proteins are required for epidermal permeability barrier formation J. Biol. Chem. 274 11038 11045 10.1074/jbc.274.16.11038 1:CAS:528:DyaK1MXis1GmsL4%3D 10196186 (Pubitemid 29191091)
8. AD Elbein JE Tropea M Mitchell GP Kaushal 1990 Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I J. Biol. Chem. 265 15599 15605 1:CAS:528:DyaK3cXmtVOjtr8%3D 2144287
9. D Elstein C Hollack JM Aerts, et al. 2004 Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type 1 Gaucher disease J. Inherit. Metab. Dis. 27 757 766 10.1023/B:BOLI.0000045756.54006.17 1:CAS:528:DC%2BD2cXovVOjsLw%3D 15505381 (Pubitemid 39433603)
10. D Elstein A Dwek D Attias, et al. 2007 Oral maintenance clinical trial with miglustat for type 1 Gaucher disease: switch from or combination with intravenous enzyme replacement Blood 110 2296 2301 10.1182/blood-2007-02-075960 1:CAS:528:DC%2BD2sXhtFCnsbzI 17609429 (Pubitemid 47523147)
11. IB Enquist E Nilsson A Ooka, et al. 2006 Effective cell and gene therapy in a murine model of Gaucher disease Proc. Natl. Acad. Sci. USA 103 13819 13824 10.1073/pnas.0606016103 1:CAS:528:DC%2BD28XpvFSlurs%3D 16954197 (Pubitemid 44413991)
12. AH Futerman JL Sussman M Horowitz I Silman A Zimran 2004 New directions in the treatment of Gaucher disease Trends Pharmacol Sci. 25 147 151 10.1016/j.tips.2004.01.004 1:CAS:528:DC%2BD2cXhslCjtLg%3D 15019270 (Pubitemid 38264505)
13. P Giraldo P Latre P Alfonso, et al. 2006 Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher disease Hematologica 91 703 706 1:CAS:528: DC%2BD28Xls1SrtLk%3D
14. GA Grabowski NW Barton G Pastores, et al. 1995 Enzyme therapy in Type I Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources Ann. Int. Med. 122 33 39 1:STN:280:DyaK2M%2FnslaisA%3D%3D 7985893
15. GA Grabowski K Kacena AJ Cole, et al. 2009 Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1 Genet Med. 11 92 100 10.1097/GIM.0b013e31818e2c19 1:CAS:528:DC%2BD1MXhvVSksL0%3D 19265748
16. CE Hollak D Hughes IN van Schaik N Schwierin B Bembi 2009 Miglustat (Zavesca®) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme Pharmacoepidemiol. Drug Saf. 18 770 777 10.1002/pds.1779 1:CAS:528:DC%2BD1MXht1WqtrrK 19507165
17. J Inokuchi NS Radin 1987 Preparation of the active isomer 1-phenyl-2-decanoyl-amino-3-morpholino-1-propanol inhibitor of murine glucocerebrosidase synthase J Lipid Chem. 28 565 571 1:CAS:528: DyaL2sXkvFamsb8%3D
18. M Jeyakumar F Norflus CJ Tifft, et al. 2001 Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation Blood 97 327 329 10.1182/blood.V97.1.327 1:CAS:528:DC%2BD3MXis1Cgsw%3D%3D 11133779 (Pubitemid 32061278)
19. M Jeyakumar R Dwek T Butters F Platt 2005 Storage solutions: treating lysosomal disorders of the brain Nat. Rev. Neurosci. 6 713 725 16049428
20. PS Kishnani M DiRocco P Kaplan, et al. 2009 A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1 Mol. Genet. Med. 10.1016/j.ymgme.2008.12.015
21. M Langeveld KJM Ghauharali HP Sauerwein, et al. 2008 Type 1 Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance J. Clin. Endocrinol. Metab. 93 845 851 10.1210/jc.2007-1702 1:CAS:528:DC%2BD1cXjsFynurs%3D 18089699 (Pubitemid 351398562)
22. L Lee A Abe JA Shayman 1999 Improved inhibitors of glucosylceramide synthase J. Biol. Chem. 274 14662 14665 10.1074/jbc.274.21.14662 1:CAS:528:DyaK1MXks1Kqsr8%3D 10329660 (Pubitemid 29265844)
23. RL Lieberman BA Wustman P Huertas, et al. 2007 Structure of acid-β-glucosidase with pharmacological chaperone provides insight into Gaucher disease Nature Chem Biol. 3 101 107 10.1038/nchembio850 1:CAS:528:DC%2BD2sXntVGrtA%3D%3D (Pubitemid 46134996)
24. K McEachern JB Nietupski W-L Chuang, et al. 2006 AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease J. Gene. Med. 8 719 729 10.1002/jgm.901 1:CAS:528:DC%2BD28XnsVWjur0%3D 16528760
25. KA McEachern J Fung S Komarnitsky, et al. 2007 A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease Mol. Genet. Metab. 91 259 267 10.1016/j.ymgme.2007.04.001 1:CAS:528:DC%2BD2sXmtVejsLk%3D 17509920 (Pubitemid 46819125)
26. A Mehta 2008 Gaucher disease: unmet treatment needs Acta Paediatr. 97 83 87 10.1111/j.1651-2227.2008.00653.x (Pubitemid 351421296)
27. T-W Mu DST Ong Y-J Wang WE Balch JR Yates L Segatori JW Kelly 2008 Chemical and biological approaches synergize to ameliorate protein-folding diseases Cell 134 769 761 10.1016/j.cell.2008.06.037 1:CAS:528: DC%2BD1cXhtFCqs7nL 18775310
28. GM Pastores NL Barnett EH Kolodny 2005 An open-label, noncomparative study of miglustat in type 1 Gaucher disease: efficacy and tolerability over 24 months of treatment Clin Ther. 27 1215 1227 10.1016/j.clinthera.2005.08.004 1:CAS:528:DC%2BD2MXhtFWgurfM 16199246 (Pubitemid 41393915)
29. GM Pastores P Giraldo P Cherin A Mehta 2009 Goal-oriented therapy with miglustat in Gaucher disease Curr. Med. Res. Opin. 25 23 37 10.1185/ 03007990802576518 1:CAS:528:DC%2BD1MXkvFCktrw%3D 19210136
30. FM Platt GR Neises G Reinkensmeier, et al. 1997 Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin Science 276 428 431 10.1126/science.276.5311.428 1:CAS:528:DyaK2sXis1Knsrk%3D 9103204 (Pubitemid 27180707)
31. Y Shaaltiel D Bartfeld S Hashmueli, et al. 2007 Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system Plant Biotechnol J. 5 579 590 10.1111/j.1467-7652.2007.00263.x 1:CAS:528:DC%2BD2sXhtVemt7bM 17524049 (Pubitemid 47196361)
32. K Starzyk S Richards J Yee SE Smith W Kingma 2007 The long-term international safety experience of imiglucerase therapy for Gaucher disease Mol. Genet. Metab. 90 157 163 10.1016/j.ymgme.2006.09.003 1:CAS:528: DC%2BD2sXnsl2ktQ%3D%3D 17079176 (Pubitemid 46108612)
33. RA Steet S Chung B Wustman A Powe H Do SA Kornfeld 2006 The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanisms Proc. Natl. Acad. Sci. USA 103 13813 13818 10.1073/pnas.0605928103 1:CAS:528:DC%2BD28XpvFSlur0%3D 16945909 (Pubitemid 44413990)
34. SM van Patten H Hughes MR Huff, et al. 2007 Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease Glycobiology 17 467 478 10.1093/glycob/cwm008 17251309 (Pubitemid 47049935)
35. NJ Weinreb J Charrow HC Andersson, et al. 2002 Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2-5 years of treatment: a report from the Gaucher Registry Am. J. Med. 113 112 119 10.1016/S0002-9343(02)01150-6 1:CAS:528:DC%2BD38XlsVKru74%3D 12133749 (Pubitemid 34804747)
36. N Weinreb J Taylor T Cox J Yee S vom Dahl 2008 A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase Am. J. Hematol. 83 890 895 10.1002/ajh.21280 1:CAS:528:DC%2BD1MXps1emtw%3D%3D 18819093
37. JE Wraith 2006 Limitations of enzyme replacement therapy; current and future J. Inherit. Metab. Dis. 29 442 447 10.1007/s10545-006-0239-6 1:CAS:528:DC%2BD28XlsV2ltbs%3D 16763916 (Pubitemid 43880649)
38. Y-H Xu B Quinn D Witte GA Grabowski 2003 Viable mouse models of acid β-glucosidase deficiency Am. J. Pathol. 163 2093 2101 1:CAS:528: DC%2BD3sXpsVWlurg%3D 14578207
39. Z Yu AR Sawkar LJ Whalen C-H Wong JW Kelly 2007 Isofagomine-and 2, 5-anhydro-2, 5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention J. Med. Chem. 50 94 100 10.1021/jm060677i 1:CAS:528:DC%2BD28XhtlansbnL 17201413 (Pubitemid 46105502)
40. H Zhao M Przybylska I-H Wu, et al. 2007 Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes Diabetes 56 1210 1218 10.2337/db06-0719 1:CAS:528: DC%2BD2sXltlantb4%3D 17470562 (Pubitemid 46715599)
41. A Zimran Y Ilan D Elstein 2009 Enzyme replacement therapy for mild patients with Gaucher disease Am. J. Hematol. 10.1002/ajh.21369 19229987